These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10778464)

  • 21. Changes in urinary risk profile after short-term low sodium and low calcium diet in recurrent Swiss kidney stone formers.
    Seeger H; Kaelin A; Ferraro PM; Weber D; Jaeger P; Ambuehl P; Robertson WG; Unwin R; Wagner CA; Mohebbi N
    BMC Nephrol; 2017 Dec; 18(1):349. PubMed ID: 29202723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines.
    Skolarikos A; Straub M; Knoll T; Sarica K; Seitz C; Petřík A; Türk C
    Eur Urol; 2015 Apr; 67(4):750-63. PubMed ID: 25454613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol.
    Levy FL; Adams-Huet B; Pak CY
    Am J Med; 1995 Jan; 98(1):50-9. PubMed ID: 7825619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etiology and treatment of urolithiasis.
    Pak CY
    Am J Kidney Dis; 1991 Dec; 18(6):624-37. PubMed ID: 1962646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urinary citrate and renal stone disease: the preventive role of alkali citrate treatment.
    Caudarella R; Vescini F
    Arch Ital Urol Androl; 2009 Sep; 81(3):182-7. PubMed ID: 19911682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preventive Kidney Stones: Continue Medical Education.
    Assadi F; Moghtaderi M
    Int J Prev Med; 2017; 8():67. PubMed ID: 28966756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.
    Stoller ML; Chi T; Eisner BH; Shami G; Gentle DL
    J Urol; 2009 Mar; 181(3):1140-4. PubMed ID: 19152919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of Hypercalciuria.
    Krieger NS; Asplin JR; Frick KK; Granja I; Culbertson CD; Ng A; Grynpas MD; Bushinsky DA
    J Am Soc Nephrol; 2015 Dec; 26(12):3001-8. PubMed ID: 25855777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal stone disease: Causes, evaluation and medical treatment.
    Heilberg IP; Schor N
    Arq Bras Endocrinol Metabol; 2006 Aug; 50(4):823-31. PubMed ID: 17117307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dietary style and acid load in an Italian population of calcium kidney stone formers.
    Vezzoli G; Dogliotti E; Terranegra A; Arcidiacono T; Macrina L; Tavecchia M; Pivari F; Mingione A; Brasacchio C; Nouvenne A; Meschi T; Cusi D; Spotti D; Montanari E; Soldati L
    Nutr Metab Cardiovasc Dis; 2015 Jun; 25(6):588-93. PubMed ID: 25921845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Substituting milk for apple juice does not increase kidney stone risk in most normocalciuric adults who form calcium oxalate stones.
    Massey LK; Kynast-Gales SA
    J Am Diet Assoc; 1998 Mar; 98(3):303-8. PubMed ID: 9508013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic abnormalities associated with calyceal diverticular stones.
    Auge BK; Maloney ME; Mathias BJ; Pietrow PK; Preminger GM
    BJU Int; 2006 May; 97(5):1053-6. PubMed ID: 16643491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcium nephrolithiasis and distal tubular acidosis in type 1 glycogen storage disease.
    Iida S; Matsuoka K; Inoue M; Tomiyasu K; Noda S
    Int J Urol; 2003 Jan; 10(1):56-8. PubMed ID: 12534929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest.
    Zerwekh JE; Odvina CV; Wuermser LA; Pak CY
    J Urol; 2007 Jun; 177(6):2179-84. PubMed ID: 17509313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical therapy, calcium oxalate urolithiasis.
    Ruml LA; Pearle MS; Pak CY
    Urol Clin North Am; 1997 Feb; 24(1):117-33. PubMed ID: 9048856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stone formation in genetic hypercalciuric rats.
    Bushinsky DA; Grynpas MD; Nilsson EL; Nakagawa Y; Coe FL
    Kidney Int; 1995 Dec; 48(6):1705-13. PubMed ID: 8587230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nephrolithiasis: acute management and prevention.
    Wasserstein AG
    Dis Mon; 1998 May; 44(5):196-213. PubMed ID: 9656969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of recurrent nephrolithiasis.
    Goldfarb DS; Coe FL
    Am Fam Physician; 1999 Nov; 60(8):2269-76. PubMed ID: 10593318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ambulatory diagnostic evaluation of 389 recurrent renal stone formers. A proposal for clinical classification and investigation.
    Wikström B; Backman U; Danielson BG; Fellström B; Johansson G; Ljunghall S
    Klin Wochenschr; 1983 Jan; 61(2):85-90. PubMed ID: 6843037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of acidosis on urine supersaturation and stone formation in genetic hypercalciuric stone-forming rats.
    Bushinsky DA; Grynpas MD; Asplin JR
    Kidney Int; 2001 Apr; 59(4):1415-23. PubMed ID: 11260403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.